<DOC>
	<DOCNO>NCT01919879</DOCNO>
	<brief_summary>This multicentric , phase II open label study.75 patient expect randomized 35 center . The main objective ass efficacy safety Afatinib -cetuximab combo versus cetuximab alone treatment patient refractory wtKRAS metastatic colorectal cancer .</brief_summary>
	<brief_title>Dual Targeting EGFR With Cetuximab Afatinib Treat Refractory wtKRAS Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Patients sign inform consent enrol one two group . Group A receive Afatinib ( 40mg per day ) Cetuximab ( 500mg/m2 ) every two week progression . Group B receive Cetuximab ( 500mg/m2 ) alone every two week progression progression , patient group B receive afatinib ( group A treatment ) progression . The criteria evaluation tumor response progression document CT scan accord RECIST criterion version 1.1 . Patient also sign inform consent participate biological study . The aim translational study collect tumor blood sample order determine , biological factor predictive response treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Metastatic colorectal cancer express wtKRAS status 2 . No previous EGFR target therapy . 3 . Must fail prior regimen contain irinotecan metastatic disease prior regimen contain oxaliplatin metastatic disease 4 . Must previously receive thymidylate synthase inhibitor ( eg , fluorouracil , capecitabine , raltitrexed , fluorouraciluracil ) point treatment colorectal cancer ( CRC ) 5 . Life expectancy least 3 month . 6 . Patient ECOG ≤ 1 7 . Patients age ≥ 18 . 8 . Patient measurable lesion accord RECIST criterion ( version 1.1 ) spiral CT scan define ≥ 10 mm long diameter 2X slice thickness extra nodal lesion and/or &gt; 15 mm short axis diameter nodal lesion 9 . Patient able receive adequate oral nutrition ≥ 1500 calorie per day free significant nausea vomit 10 . Patient adequate organ function : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Haemoglobin ≥ 9 g/dL Platelets ( PTL ) ≥ 100 x 109/L AST/ALT ≤ 3 x ULN ( ≤ 5 x ULN case liver metastasis ) GammaGT &lt; 3 x ULN ( &lt; 5 x ULN case liver involvement ) Bilirubin ≤ 1.5 x ULN Creatinine clearance ≥ 50 mL/min ( Cockcroft Gault formula ) 11 . Adequate contraception applicable . 12 . Ability take oral medication opinion investigator 13 . Patient able willing comply study procedure per protocol 14 . Patient able understand willing sign date write voluntary informed consent form screen visit prior protocolspecific procedure 15 . Patient affiliate social security regimen 1 . Previous EGFR target therapy . 2 . Mutant KRAS status 3 . Prior severe reaction monoclonal antibody 4 . No heart failure coronary heart disease symptom Clinically relevant cardiovascular abnormality , judge investigator , , limit , uncontrolled hypertension , congestive heart failure NYHA classification &gt; III , unstable angina , myocardial infarction within six month prior randomisation , poorly control arrhythmia 5 . Cardiac leave ventricular dysfunction rest ejection fraction less institutional low limit normal ( low limit normal defined institution , low limit 50 % ) 6 . Symptomatic brain metastasis require treatment 7 . Major surgery within 28 day minor surgery within 14 day start study treatment 8 . Radiotherapy le two week prior start study treatment 9 . Systemic chemotherapy , hormonal therapy , immunotherapy ≤ 21 day study treatment 10 . No major comorbidity may preclude delivery treatment active infection ( HIV chronic hepatitis B C ) uncontrolled diabetes . 11 . Concomitant occurrence another cancer , history cancer within past five year except situ carcinoma cervix treat basal cell carcinoma squamous cell carcinoma . 12 . Known preexist interstitial lung disease 13 . Significant recent acute gastrointestinal disorder diarrhea major symptom e.g. , Crohn 's disease , malabsorption , CTCAE grade &gt; 2 diarrhea etiology 14 . Pregnant woman lactate woman . 15 . Persons deprive liberty guardianship . 16 . Psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . 17 . Previous history keratitis , ulcerative keratitis severe dry eye .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chemotherapy refractory</keyword>
	<keyword>wtKRAS metastatic colorectal cancer</keyword>
	<keyword>cross</keyword>
</DOC>